The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; A randomized trial

British Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2009, Pages 662-668

  Dawson, Jesse ^a   Quinn, Terrence J ^a   Harrow, Craig ^a   Lees, Kennedy R ^a   Walters, Matthew R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Stroke; Uric acid; Xanthine oxidase

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; PLACEBO; URIC ACID; XANTHINE OXIDASE;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; BRAIN BLOOD VESSEL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FLOW RATE; HUMAN; INFLAMMATION; MIDDLE CEREBRAL ARTERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONSILLITIS; URIC ACID BLOOD LEVEL;

AGED; ALLOPURINOL; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CEREBROVASCULAR CIRCULATION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MIDDLE AGED; STATISTICS AS TOPIC; STROKE; URIC ACID; VASODILATION; XANTHINE OXIDASE;

EID: 70449334334     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03497.x     Document Type: Article

References (31)

1. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of Stroke in Germany - The Erlangen Stroke Project (espro) incidence and case fatality at 1, 3, and 12 months. Stroke 1998 29 : 2501 2506.
2. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 2006 62 : 633 644.
3. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003 34 : 1951 1956.
4. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000 9 : 2206 2212.
5. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007 14 : 1879 1886.
6. Okamoto H, Mizuno K, Horio T. Monocyte-derived multinucleated giant cells and sarcoidosis. J Dermatological Sci 2003 31 : 119 128.
7. Muir S, Harrow C, Dawson J, Lees KR, Weir CJ, Sattar N, Walters M. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke; a randomised, double blind placebo controlled trial. Stroke 2008 39 : 3303 3307.
8. Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JJF. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther 2008 26 : 247 252.
9. Dawson J, Quinn TJ, Harrow C, Lees KR, Weir CJ, Cleland SJ, Walters MR. Allopurinol and nitric oxide activity in the cerebral circulation of those with diabetes. Diabetes Care 2009 32 : 135 137.
10. Cupini LM, Diomedi M, Placidi F, Silvestrini M, Giacomini P. Cerebrovascular reactivity and subcortical infarctions. Arch Neurol 2001 58 : 577 581.
11. Settakis G, Molnar C, Kerenyi L, Kollar J, Legemate D, Csiba L, Fulesdi B. Acetazolamide as a vasodilatory stimulus in cerebrovascular diseases and in conditions affecting the cerebral vasculature. Eur J Neurol 2003 10 : 609 620.
12. Ringelstein EB, Sievers C, Ecker S, Schneider PA, Otis SM. Noninvasive assessment of Co-2-induced cerebral vasomotor response in normal individuals and patients with internal carotid-artery occlusions. Stroke 1988 19 : 963 969.
13. Minematsu K, Yamaguchi T, Tsuchiya M, Ito K, Ikeda M, Omae T. Effect of Angiotensin Converting-Enzyme-Inhibitor (Captopril) on cerebral blood-flow in hypertensive patients without a history of stroke. Clin Exp Hypertens A 1987 9 : 551 557.
14. Terborg C, Gora F, Weiller C, Rother J. Reduced vasomotor reactivity in cerebral microangiopathy - a study with near-infrared spectroscopy and transcranial Doppler sonography. Stroke 2000 31 : 924 929.
15. Sterzer P, Meintzschel F, Rosler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001 32 : 2817 2820.
16. Walters M, Muir S, Shah I, Lees K. Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction. Stroke 2004 35 : 1899 1902. (Pubitemid 38971872)
17. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999 33 : 719 725.
18. Schwertfeger N, Neu P, Schlattmann P, Lemke H, Heuser I, Bajbouj M. Cerebrovascular reactivity over time course in healthy subjects. J Neurol Sci 2006 249 : 135 139.
19. Zocalli C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006 17 : 1466 1471.
20. Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. J Am Coll Cardiol 2001 38 : 1850 1858.
21. Hare JM, Mangal B, Brown J, Fisher C, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP. Impact of oxypurinol in patients with symptomatic heart failure. J Am Coll Cardiol 2008 51 : 2301 2309.
22. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005 91 : 749 753.
23. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004 94 : 932 935.
24. Doehner W, Anker SD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart 2005 91 : 707 709.
25. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006 114 : 2508 2516.
26. Dahl A, Russell D, Rootwelt K, Nyberghansen R, Kerty E. Cerebral vasoreactivity assessed with transcranial Doppler and regional cerebral blood-flow measurements - dose, serum concentration, and time-course of the response to acetazolamide. Stroke 1995 26 : 2302 2306.
27. Hamann GF, Stoll M, Jost V, Bompotti UAR, Fitridge R, Schimrigk K. Time course of acetazolamide effect in normal persons. J Neuroimaging 1996 6 : 29 31.
28. West GA, Leppla DC, Simard JM. Effects of external pH on ionic currents in smooth-muscle cells from the basilar artery of the guinea-pig. Circ Res 1992 71 : 201 209.
29. Hauge A, Nicolaysen G, Thoresen M. Acute effects of acetazolamide on cerebral blood-flow in man. Acta Physiol Scand 1983 117 : 233 239.
30. Pretnar-Oblak J, Sabovic M, Vidmar G, Zaletel M. Evaluation of L-arginine reactivity in comparison with flow-mediated dilatation and intima-media thickness. Ultrasound Med Biol 2007 33 : 1546 1551.
31. Prettlar-Oblak J, Sabovic M, Sebestjen M, Pogacnik T, Zaletel M. Influence of atorvastatin treatment on l-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 2006 37 : 2540 2545.